Department of Medicine and Microbiology, The University of North Carolina, Chapel Hill, NC, USA.
J Virol. 2011 Oct;85(19):10144-53. doi: 10.1128/JVI.05035-11. Epub 2011 Jul 27.
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1), the principal viral oncoprotein and a member of the tumor necrosis factor receptor superfamily, is a constitutively active membrane signaling protein that regulates multiple signal transduction pathways via its C-terminal-activating region 1 (CTAR1) and CTAR2, and also the less-studied CTAR3. Because protein sumoylation among other posttranslational modifications may regulate many signaling pathways induced by LMP1, we investigated whether during EBV latency LMP1 regulates sumoylation processes that control cellular activation and cellular responses. By immunoprecipitation experiments, we show that LMP1 interacts with Ubc9, the single reported SUMO-conjugating enzyme. Requirements for LMP1-Ubc9 interactions include enzymatically active Ubc9: expression of inactive Ubc9 (Ubc9 C93S) inhibited the LMP1-Ubc9 interaction. LMP1 CTAR3, but not CTAR1 and CTAR2, participated in the LMP1-Ubc9 interaction, and amino acid sequences found in CTAR3, including the JAK-interacting motif, contributed to this interaction. Furthermore, LMP1 expression coincided with increased sumoylation of cellular proteins, and disruption of the Ubc9-LMP1 CTAR3 interaction almost completely abrogated LMP1-induced protein sumoylation, suggesting that this interaction promotes the sumoylation of downstream targets. Additional consequences of the disruption of the LMP1 CTAR3-Ubc9 interaction revealed effects on cellular migration, a hallmark of oncogenesis. Together, these data demonstrate that LMP1 CTAR3 does in fact function in intracellular signaling and leads to biological effects. We propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis.
EB 病毒(EBV)潜伏膜蛋白 1(LMP1)是主要的病毒癌蛋白,也是肿瘤坏死因子受体超家族的成员,是一种组成性激活的膜信号蛋白,通过其 C 端激活区 1(CTAR1)和 CTAR2,以及研究较少的 CTAR3,调节多种信号转导途径。由于蛋白质的 SUMO 化等翻译后修饰可能调节 LMP1 诱导的许多信号通路,我们研究了 EBV 潜伏期间 LMP1 是否调节控制细胞激活和细胞反应的 SUMO 化过程。通过免疫沉淀实验,我们表明 LMP1 与 Ubc9 相互作用,Ubc9 是唯一报道的 SUMO 缀合酶。LMP1-Ubc9 相互作用的要求包括具有酶活性的 Ubc9:表达无活性的 Ubc9(Ubc9 C93S)抑制了 LMP1-Ubc9 相互作用。LMP1 CTAR3,但不是 CTAR1 和 CTAR2,参与 LMP1-Ubc9 相互作用,并且在 CTAR3 中发现的氨基酸序列,包括 JAK 相互作用基序,有助于这种相互作用。此外,LMP1 的表达与细胞蛋白的 SUMO 化增加一致,并且破坏 Ubc9-LMP1 CTAR3 相互作用几乎完全消除了 LMP1 诱导的蛋白质 SUMO 化,这表明这种相互作用促进了下游靶标的 SUMO 化。破坏 LMP1 CTAR3-Ubc9 相互作用的其他后果揭示了对细胞迁移的影响,这是致癌作用的一个标志。总之,这些数据表明 LMP1 CTAR3 实际上在细胞内信号转导中起作用,并导致生物学效应。我们提出,LMP1 通过与 Ubc9 相互作用,调节 SUMO 化过程,调节影响与致癌作用相关的表型变化的信号转导途径。